Log in

OTCMKTS:GOVXGeovax Labs Stock Price, Forecast & News

$0.39
+0.02 (+5.41 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.36
Now: $0.39
$0.42
50-Day Range
$0.20
MA: $0.35
$0.50
52-Week Range
$0.12
Now: $0.39
$2,880.00
Volume112,894 shs
Average Volume595,872 shs
Market Capitalization$5.39 million
P/E RatioN/A
Dividend YieldN/A
Beta1.23
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; CaroGen Corporation; Virometix AG; U.S. Department of Defense; Geneva Foundation; Enesi Pharma; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GOVX
Previous SymbolNASDAQ:GOVX
CUSIPN/A
Phone678-384-7220

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.18 million
Book Value($0.16) per share

Profitability

Net Income$-2,370,000.00
Net Margins-148.30%

Miscellaneous

Employees8
Market Cap$5.39 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive GOVX News and Ratings via Email

Sign-up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.

Geovax Labs (OTCMKTS:GOVX) Frequently Asked Questions

How has Geovax Labs' stock been impacted by COVID-19 (Coronavirus)?

Geovax Labs' stock was trading at $0.28 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GOVX shares have increased by 39.3% and is now trading at $0.39. View which stocks have been most impacted by Coronavirus.

When is Geovax Labs' next earnings date?

Geovax Labs is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Geovax Labs.

How were Geovax Labs' earnings last quarter?

Geovax Labs Inc (OTCMKTS:GOVX) announced its quarterly earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.13) earnings per share for the quarter. The biotechnology company had revenue of $0.72 million for the quarter. View Geovax Labs' earnings history.

Has Geovax Labs been receiving favorable news coverage?

News coverage about GOVX stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Geovax Labs earned a news sentiment score of -1.1 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutGeovax Labs.

Who are some of Geovax Labs' key competitors?

What other stocks do shareholders of Geovax Labs own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Geovax Labs investors own include Ekso Bionics (EKSO), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Dare Bioscience (DARE), Cidara Therapeutics (CDTX), Sanofi (SNY), Vaxart (VXRT), Quest Diagnostics (DGX) and Micron Technology (MU).

Who are Geovax Labs' key executives?

Geovax Labs' management team includes the following people:
  • Mr. David Alan Dodd, Chairman, CEO & Pres (Age 69)
  • Dr. Harriet Latham Robinson, Co-Founder, Chief Scientific Officer Emeritus & Director (Age 81)
  • Mr. Mark W. Reynolds CPA, CPA, CFO & Corp. Sec. (Age 57)
  • Dr. Farshad Guirakhoo, Chief Scientific Officer (Age 66)
  • Mr. Donald G. Hildebrand, Founder, Chairman Emeritus & Consultant (Age 78)

What is Geovax Labs' stock symbol?

Geovax Labs trades on the OTCMKTS under the ticker symbol "GOVX."

How do I buy shares of Geovax Labs?

Shares of GOVX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Geovax Labs' stock price today?

One share of GOVX stock can currently be purchased for approximately $0.39.

How big of a company is Geovax Labs?

Geovax Labs has a market capitalization of $5.39 million and generates $1.18 million in revenue each year. Geovax Labs employs 8 workers across the globe.

What is Geovax Labs' official website?

The official website for Geovax Labs is www.geovax.com.

How can I contact Geovax Labs?

Geovax Labs' mailing address is 1900 LAKE PARK DRIVE SUITE 380, SMYRNA GA, 30080. The biotechnology company can be reached via phone at 678-384-7220 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.